Opinion|Videos|January 2, 2025
Emerging Data for Odronextamab in DLBCL
Panelists discuss how emerging data on odronextamab in diffuse large B-cell lymphoma suggest its potential to play a significant role in therapy, with promising results that may position it alongside or as a superior option compared with currently approved bispecifics.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What do the emerging data on odronextamab in diffuse large B-cell lymphoma suggest about its future role in therapy, and how does it compare to currently approved bispecifics?
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Trump Announces Timeline for 100% Generic Drug Tariffs Beginning in 2028, 200% in 2029
2
Fifth Death Confirmed in NYC Legionnaires' Outbreak
3
Eplontersen Misses Primary End Point in Phase 3 ATTR-CM Cardiovascular Outcomes Trial
4
Contextualizing Golcadomide's Efficacy Signal in the RRFL Landscape
5